![Banmeet Anand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Banmeet Anand
Corporate Officer/Principal bij HARPOON THERAPEUTICS, INC.
Profiel
Banmeet Anand is currently the Senior Vice President-Translational Medicine at Harpoon Therapeutics, Inc. Prior to this, he worked as the Vice President & Head-Nonclinical Development at Molecular Templates, Inc. He holds a doctorate degree from the University of Missouri.
Actieve functies van Banmeet Anand
Bedrijven | Functie | Begin |
---|---|---|
HARPOON THERAPEUTICS, INC. | Corporate Officer/Principal | 06-07-2022 |
Eerdere bekende functies van Banmeet Anand
Bedrijven | Functie | Einde |
---|---|---|
MOLECULAR TEMPLATES, INC. | Corporate Officer/Principal | - |
Opleiding van Banmeet Anand
University of Missouri | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MOLECULAR TEMPLATES, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |